Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based study

C.A. Purdie, L. Baker, A. Ashfield, S. Chatterjee, L.B. Jordan, P. Quinlan, D. J. A. Adamson, J.A. Dewar, A.M. Thompson

    Research output: Contribution to journalArticle

    28 Citations (Scopus)

    Abstract

    BACKGROUND: This study assessed the impact of human epidermal growth factor receptor 2 (HER2) status on the outcomes in an unselected population of breast cancer patients who did not receive HER2-targeted therapy.

    METHODS: HER2 status by immunohistochemistry and fluorescence in situ hybridisation was compared with clinicopathological data, overall survival (OS) and disease-free survival (DFS) for all patients presenting with breast cancer over 3 years.

    RESULTS: In 865 patients (median follow up 6.02 years), HER2 positivity was identified in 13.3% of all cancers and was associated with higher tumour grade (P<10(-8)), lymphovascular invasion (P<0.001) and axillary nodal metastasis (P=0.003). There was a negative association with oestrogen-receptor (ER) and progesterone-receptor expression (P<10(-8)), but the majority (57%) of HER2+ tumours were ER+HER2 positivity was associated with poorer OS (P=0.0046) and DFS (P=0.0001) confined to the lymph node-positive (LN+) and ER+ subgroups.

    CONCLUSION: HER2-positive cancers were less common in this population-based cohort than most selected series. The association of HER2 positivity with poor prognosis was confined to the ER+ and LN+ subgroups. The survival deficit for the 7.5% of patients with ER+/HER2+ cancer compared with ER+/HER2- patients points to a significant subgroup of women who may not (currently) be considered for HER2-directed therapy. British Journal of Cancer (2010) 103, 475-481. doi:10.1038/sj.bjc.6605799 www.bjcancer.com Published online 27 July 2010 (C) 2010 Cancer Research UK

    Original languageEnglish
    Pages (from-to)475-481
    Number of pages7
    JournalBritish Journal of Cancer
    Volume103
    Issue number4
    DOIs
    Publication statusPublished - 10 Aug 2010

    Keywords

    • breast cancer
    • oestrogen receptor
    • HER2
    • survival
    • population
    • IN-SITU HYBRIDIZATION
    • ADJUVANT CHEMOTHERAPY
    • FOLLOW-UP
    • MONOCLONAL-ANTIBODY
    • PROGNOSTIC FACTORS
    • IMAGE-ANALYSIS
    • POOR SURVIVAL
    • NEU ONCOGENE
    • AMPLIFICATION
    • TRASTUZUMAB

    Cite this

    Purdie, C. A., Baker, L., Ashfield, A., Chatterjee, S., Jordan, L. B., Quinlan, P., Adamson, D. J. A., Dewar, J. A., & Thompson, A. M. (2010). Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based study. British Journal of Cancer, 103(4), 475-481. https://doi.org/10.1038/sj.bjc.6605799